Results vary by medication and individual. The phrase “up to 20% of your body weight” is based on clinical trial data for prescription weight-management medication used alongside a reduced-calorie diet and increased physical activity. This figure represents the upper range of outcomes observed in clinical studies and is not the average result or a guarantee of weight loss. Treatment should be undertaken only under the guidance of a registered medical practitioner and in accordance with applicable Indian prescribing guidelines. Individual results may vary and are not guaranteed.
Average weight loss
~20%
of body weight lost by members on doctor-led GLP-1 programs in India over ~4 months.
Trial-based results
15–22%
body weight lost in trials with semaglutide (~15%) and tirzepatide (up to ~22%) over 16–18 months.
Generic access
40+
generic semaglutide brands now available in India since the patent expired in March 2026.
Clinically proven options,
prescribed by Indian practitioners.
Weekly injection
Reduces appetite and supports sustainable weight loss.
Reduces appetite and supports sustainable weight loss.